Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2021 - 11 - 04    tags : Genetown    save search

Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
Published: 2021-11-04 (Crawled : 18:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.06% H: 0.26% C: 0.19%
LLY | News | $745.69 1.96% -0.16% 2M twitter stocktwits trandingview |
Health Technology
| | O: 3.16% H: 0.0% C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K twitter stocktwits trandingview |
Health Technology
| | O: -0.24% H: 7.69% C: 7.59%

kidney
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress
Published: 2021-11-04 (Crawled : 13:00) - biospace.com/
LJPC | $6.22 0.0% twitter stocktwits trandingview |
Health Technology
| | O: 2.14% H: 0.23% C: -5.12%

financial results results
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
Published: 2021-11-04 (Crawled : 12:00) - biospace.com/
IMV | $0.8225 -2.74% 45K twitter stocktwits trandingview |
Health Technology
| | O: -0.61% H: 2.78% C: 0.62%

results conference
Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11
Published: 2021-11-04 (Crawled : 12:00) - biospace.com/
MITO | $0.32 0.25% twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 1.75% C: 0.0%

financial results results iot
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
Published: 2021-11-04 (Crawled : 12:00) - biospace.com/
ORTX | $16.7 0.0% 370K twitter stocktwits trandingview |
Health Technology
| | O: 0.49% H: 1.46% C: -10.19%

financial results results
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
Published: 2021-11-04 (Crawled : 11:00) - biospace.com/
BCYC | $22.68 0.49% 0.49% 160K twitter stocktwits trandingview |
Health Technology
| | O: 1.79% H: 0.86% C: -0.05%

solid tumors trial
Gainers vs Losers
78% 22%

Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M twitter stocktwits trandingview |

AGBA | $2.94 135.2% 57.48% 66M twitter stocktwits trandingview |
Finance

EDBL | News | $6.46 71.81% 41.8% 2M twitter stocktwits trandingview |

MTC | $2.25 44.23% 30.67% 6M twitter stocktwits trandingview |
Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M twitter stocktwits trandingview |
Finance

SHIM | $3.05 35.56% 26.23% 1.1M twitter stocktwits trandingview |

HKIT | $1.345 31.86% 24.16% 390K twitter stocktwits trandingview |
Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M twitter stocktwits trandingview |
Wholesale Trade

OST | $0.512 28.0% 21.88% 290K twitter stocktwits trandingview |

POET | $1.59 27.2% 21.38% 4.2M twitter stocktwits trandingview |
Manufacturing


Your saved searches
Save your searches and get alerts when important news are released.